PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17634558-0	2007	Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.	Sorafenib	48-57	cyclin dependent kinase inhibitor 1A	Homo sapiens	114-121	
17634558-8	2007	Sorafenib also blocked vorinostat-mediated induction of p21(CIP1).	Sorafenib	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	56-59	
17634558-8	2007	Sorafenib also blocked vorinostat-mediated induction of p21(CIP1).	Sorafenib	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	60-64	
17634558-10	2007	Enforced expression of p21(CIP1) and particularly Mcl-1 significantly attenuated vorinostat/sorafenib-mediated lethality.	Sorafenib	92-101	cyclin dependent kinase inhibitor 1A	Homo sapiens	23-26	
17634558-10	2007	Enforced expression of p21(CIP1) and particularly Mcl-1 significantly attenuated vorinostat/sorafenib-mediated lethality.	Sorafenib	92-101	cyclin dependent kinase inhibitor 1A	Homo sapiens	27-31	
17634558-11	2007	CONCLUSIONS: These findings suggest that combined treatment with vorinostat and sorafenib synergistically induces apoptosis in CML cells through a process that involves Mcl-1 down-regulation and inhibition of p21(CIP1) induction.	Sorafenib	80-89	cyclin dependent kinase inhibitor 1A	Homo sapiens	209-212	
17634558-11	2007	CONCLUSIONS: These findings suggest that combined treatment with vorinostat and sorafenib synergistically induces apoptosis in CML cells through a process that involves Mcl-1 down-regulation and inhibition of p21(CIP1) induction.	Sorafenib	80-89	cyclin dependent kinase inhibitor 1A	Homo sapiens	213-217